News & Events

Press & Media

Read the latest news from TriSalus.

Press Releases

  • All
  • 2019
  • 2020
  • 2021
  • 2022
  • 2023

TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases

April 20, 2023

TriSalus Life Sciences to Showcase Treatment Platform and Present Pressure-Enabled Regional Immuno-Oncology (PERIO) Data at the Society of Interventional Radiology’s 2023 Annual Scientific Meeting

February 28, 2023

TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business

February 21, 2023

TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Data for Pressure-Enabled Regional Immuno-Oncology™-01 and -02 Studies

February 16, 2023

TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progress and Pre-clinical Research Developments

December 15, 2022

TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical Studies

November 20, 2022

TriSalus Life Sciences to Become Publicly Traded Through Merger with MedTech Acquisition Corporation

November 12, 2022

TriSalus Life Sciences Provides Update on Development of Immunotherapy Platform Approach for Liver and Pancreatic Tumors

June 22, 2022

TriSalus Life Sciences to Present at the Society of Interventional Radiology’s 2022 Annual Scientific Meeting

June 6, 2022

TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial, Studying the Delivery of SD-101 via Pressure-Enabled Drug Delivery in Adults with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

May 10, 2022

TriSalus Life Sciences Opens Its First Research Laboratory on Lifespan Health System’s Campus

April 12, 2022

TriSalus Life Sciences Expands Clinical Executive Team and Scientific Advisors in Support of Company’s Focus to Overcome Liver and Pancreatic Cancer Treatment Barriers and Enable More Patients to Benefit From Immunotherapy

February 10, 2022

TriSalus Life Sciences Announces Collaboration with the University of Colorado Anschutz Medical Campus to Advance Research on Innovative Immuno-oncology Treatments for Patients With Liver and Pancreatic Tumors

January 19, 2022

Global Liver Institute and TriSalus Life Sciences Partner To Launch “Liver Central,” a New Resource Hub for Liver Cancer Researchers, Clinicians and Patients

January 6, 2022

TriSalus Life Sciences Announces the Unexpected Passing of Board Director Alan Mendelson

October 11, 2021

TriSalus Life Sciences Appoints Industry Expert Sean Murphy to Board of Directors

October 6, 2021

TriSalus Life Sciences Announces First Patient Enrolled in PERIO-01 Clinical Trial to Evaluate Delivery of SD-101 via Pressure-Enabled Drug Delivery in Uveal Melanoma Liver Metastases

September 7, 2021

TriSalus Life Sciences Presents Data at American Association of Cancer Research Showing Reduced Liver Tumor Burden from Toll-Receptor Agonists

April 14, 2021

TriSalus Life Sciences and MD Anderson Announce Strategic Research Collaboration to Evaluate Treatment of Solid Tumors

April 8, 2021

TriSalus Life Sciences Receives Expanded Reimbursement Authorization from CMS for TriNav Infusion System

February 8, 2021
Load More

IMPORTANT NOTICE

You are now leaving the Trisalus life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus’ standards.

Third Party Sites

TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.

Thank you for visiting our site.

CANCEL